Jeffrey Yap, PhD

Languages

  • English

Academic Information

  • Departments: Radiology and Imaging Sciences - Research Associate Professor
  • Divisions: Clinical Radiology
  • Cancer Center Programs: Experimental Therapeutics

Academic Office Information

  • 801-213-5650
  • Huntsman Cancer Institute
    2000 Circle of Hope, Room: 3264
    Salt Lake City, UT 84112

Academic Bio

Jeffrey Yap, PhD, is a research associate professor in the Department of Radiology at the University of Utah. He is also the Associate Director of the Center for Quantitative Cancer Imaging, the Co-Leader of the Sarcoma Disease Oriented Research Team, and a member of the Experimental Therapeutics Program at the Huntsman Cancer Institute.Dr. Yap's research interest is in the use of quantitative multimodality imaging to develop and evaluate novel cancer therapy in murine tumor models and cancer clinical trials.Dr. Yap received a Bachelor's of Science in Physics at the University of Dallas and a PhD in Medical Physics at the Unverisity of Chicago.

Education History

Type School Degree
Research Fellow Imperial College of Science & Technology
Medicine
Research Fellow
Fellowship Imperial College of Science & Technology
Medicine
Postdoctoral Research Associate
Doctoral Training University of Chicago
Medical Physics
Ph.D.
Undergraduate University of Dallas
Physics
B.S.

Global Impact

Education History

Type School Degree Country
Research Fellow Imperial College of Science & Technology
Medicine
Research Fellow United Kingdom
Fellowship Imperial College of Science & Technology
Medicine
Postdoctoral Research Associate United Kingdom

Career

Institution Description Country
Hammersmith Hospital Head of Methodology, PET Oncology Group MRC Cyclotron Unit United Kingdom

Selected Publications

Journal Article

  1. ONeill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT (08/30/2016). Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in Glioblastoma. J Neuroimaging, Epub.
  2. Ben Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S (2016). A Multicenter Phase II Trial of Regorafenib among Patients with Metastatic and/or Unresectable GI Stromal Tumor after Failure of Imatinib and Sunitinib: A Long-term Follow-Up. Ann Oncol.
  3. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM (2015). FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 15, 15.
  4. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD (2015). Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol, 33(24), 2623-31.
  5. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME (2015). A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer, 13(2), 113-23.
  6. Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, Perlman ES, Kinahan PE, Christian PE, Hoekstra OS, Dorfman GS (2015). Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials. J Nucl Med, 56(6), 955-61.
  7. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL (2014). Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 32(12), 1202-9.
  8. Bevacizumab plus ipilimumab in patients with metastatic melanoma.Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res, 2(7), 632-42.
  9. Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology.Guo M, Yap JT, Van den Abbeele AD, Lin NU, Schwartzman A (2014). Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology. Stat, 3(1), 172-186.
  10. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, ODay S, Kim K, Hodi FS, Van den Abbeele AD (2014). Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging, 14, 30.
  11. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, ODay SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE (2013). Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol, 31(26), 3182-90.
  12. Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning.Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen AB (2012). Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning. Int J Radiat Oncol Biol Phys, 82(1), e99-105.
  13. Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans.Aristophanous M, Yong Y, Yap JT, Killoran JH, Allen AM, Berbeco RI, Chen AB (2012). Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans. Radiother Oncol, 102(3), 377-82.
  14. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA (2012). ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med, 53(4), 567-74.
  15. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI (2012). Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood, 119(20), 4597-607.
  16. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD (2012). Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol, 30(19), 2401-7.
  17. Balter JM, Haffty BG, Dunnick NR, Siegel EL, Balter J, Dunnick NR, Haffty B, Siegel E, Palta J, Hahn S, Cao Y, Bentzen S, Van den Abbeele A, Luker G, Michalski J, Galvin J, Khoo V, Alber M, Low D, Mageras G, Atcher R, Yap J, Jeraj R, Jackson E, Wahl R, Deye J, Clarke L, Vikram B, Stone H, Wong R, Croft B, Farahani K, Kelloff G, Shankar L (2011). Imaging opportunities in radiation oncology. Int J Radiat Oncol Biol Phys, 79(2), 342-7.
  18. Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK (2011). Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol, 59(5), 856-62.
  19. Four-dimensional positron emission tomography: implications for dose painting of high-uptake regions.Aristophanous M, Yap JT, Killoran JH, Chen AB, Berbeco RI (2011). Four-dimensional positron emission tomography: implications for dose painting of high-uptake regions. Int J Radiat Oncol Biol Phys, 80(3), 900-8.
  20. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Janne PA, Van den Abbeele AD, Johnson BE (2011). CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol, 18(1), 54-62.
  21. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Janne PA, Johnson BE, Van den Abbeele AD (2010). New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol, 195(3), W221-8.
  22. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ (2009). Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology. Clin Cancer Res, 15(6), 1891-7.
  23. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, OMara MM, DAdamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML (2009). Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol, 27(19), 3154-60.
  24. Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial.Otero HJ, Yap JT, Patak MA, Erturk SM, Israel DA, Johnston CJ, Sakellis C, Rybicki FJ, Van den Abbeele AD, Ros PR (2009). Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. AJR Am J Roentgenol, 193(2), 326-32.
  25. Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF, Syngal S, Garber JE (2008). F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA, 299(11), 1315-9.
  26. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC (2008). Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res, 14(8), 2387-95.
  27. Laforest R, Longford D, Siegel S, Newport DF, Yap J (07/01/2007). Performance Evaluation of the microPET®—FOCUS-F120. IEEE Trans Nucl Sci, 54(1), 42-49.
  28. Wall JS, Kennel SJ, Paulus M, Gregor J, Richey T, Avenell J, Yap J, Townsend D, Weiss DT, Solomon A (2006). Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med, 47(12), 2016-24.
  29. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D (2006). Consensus recommendations for the use of 18F- FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med, 47(6), 1059-66.
  30. Carney JPJ, Yap JT, Townsend DW (2004). PET count rate performance and CT image quality of a 16-slice LSO PET/CT for clinical whole-body imaging. Radiat Phys Chem, (71), 963-965.
  31. Image-guided cancer therapy using PET/CT.Yap JT, Carney JP, Hall NC, Townsend DW (2004). Image-guided cancer therapy using PET/CT. Cancer J, 10(4), 221-33.
  32. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM (2003). Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol, 21(15), 2823-30.
  33. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris AL (2003). Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer, 89(2), 262-7.
  34. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, Jones T, Price PM, Aboagye EO (2000). In vivo imaging of drug action in patients: Modulation of 5-fluorouracil tissue pharmacokinetics by the dihydropyrimidine dehydrogenase inactivator eniluracil. Lancet, 355(9221), 2125-31.
  35. On-line measurement of exhaled [11C]CO2 during PET.Gunn RN, Ranicar A, Yap JT, Wells P, Osman S, Jones T, Cunningham VJ (2000). On-line measurement of exhaled [11C]CO2 during PET. J Nucl Med, 41(4), 605-11.
  36. A general method to correct PET data for tissue metabolites using a dual-scan approach.Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, Cunningham VJ (2000). A general method to correct PET data for tissue metabolites using a dual-scan approach. J Nucl Med, 41(4), 706-11.
  37. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET.Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG (1999). Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med, 40(11), 1848-56.
  38. Image reconstruction for dynamic PET based on low-order approximation and restoration of the sinogram.Kao CM, Yap JT, Mukherjee J, Wernick MN (1997). Image reconstruction for dynamic PET based on low-order approximation and restoration of the sinogram. IEEE Trans Med Imaging, 16(6), 738-49.

Review

  1. PET/CT today and tomorrow.Townsend DW, Carney JP, Yap JT, Hall NC (2004). PET/CT today and tomorrow. [Review]. J Nucl Med, 45 Suppl 1, 4S-14S.

Book Chapter

  1. Yap JT, Townsend DW, Hall NC (2005). Chapter 8: PET/CT in IMRT Planning. In Decker BC (Ed.), Intensity modulated radiation therapy: A clinical perspective (pp. 115-130). Hamilton.
  2. Yap JT, Cunningham VJ, Jones T, Cooper M, Chen CT, Price P (1998). Classification of dynamic PET images using a priori kinetic factors. In Quantitative functional brain imaging with PET (pp. 107-115). San Diego.
  3. Yap JT, Cooper M, Chen CT, Cunningham VJ (1996). Generation of parametric images using factor analysis of dynamic PET. In: Quantification of brain function using PET. San Diego: Academic Press.
  4. Yap JT, Kao CM, Cooper M, Chen CT, Wernick M (1996). Sinogram recovery of dynamic PET using principal component analysis and projection onto convex sets. In Quantification of brain function using PET (pp. 109-112). San Diego: Academic Press.